Project Grant R43AR086680
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $613,742 to Flex Orthopaedics, Inc. on September 19, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to optimize and conduct pre-clinical studies of a compliant intramedullary stem for revision total knee arthroplasty implants. Revision total knee arthroplasty implants frequently fail within ten years due to overconstraint that increases bearing wear and bone-implant...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Penderia Technologies Inc. $306,722 on September 19, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fabricate and characterize a distal femoral fracture fixation plate featuring an implantable, battery-free wireless sensor for intra- and postoperative monitoring of fixation plate strains. The project targets personalized postoperative...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant of $158,555 to the University of Pittsburgh under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate a wireless metamaterial interbody fusion cage for real-time assessment of lumbar spinal fusion. The project, awarded September 1, 2025, with an ultimate completion date of August 31, 2027, addresses current limitations in wireless force...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $1.696 million to Poly Orth International on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds translational pre-clinical research and development of a 3D-printed skin and bone integrated pylon (SBIP-3D) for direct skeletal attachment of limb prostheses. The technology, developed by Poly Orth International, integrates with both residual bone...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award to Reselute, Inc. provides $998,921 to develop a novel implantable orthopedic medical device and procedure to reduce recovery duration and infection risks associated with severe traumatic fractures of the long bones. The project aims to advance a 3D-printed, antibiotic-releasing intramedullary nail to improve upon current standard-of-care implants that are prone to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases, a component of the National Institutes of Health within the Department of Health and Human Services, awarded Thinks Works, PBC $306,346 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846, Assistance Listing designation R43). Thinks Works is developing the Resilient Brace, a flexible, adjustable, connected bracing system designed to treat adolescent idiopathic...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Leland Stanford Junior University $667,829 on August 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate an osteoinductive, biodegradable intramedullary implant as an adjunctive therapy for distraction osteogenesis in large orthopedic trauma and limb reconstruction. The project addresses a major limitation of the Ilizarov surgical technique—the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $396,206 on September 1, 2026, to develop and validate a radiogenomic virtual biopsy approach for femoroacetabular impingement (FAI) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project tests feasibility of linking routine magnetic resonance imaging features to bone gene expression patterns in FAI patients to enable noninvasive...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Rush University Medical Center $643,185 on June 10, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds development of validated, patient-specific computational models to predict polyethylene wear in total shoulder arthroplasty (TSA) and identify modifiable surgical, design, and rehabilitation targets to improve implant...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Novomedix LLC $314,362 on September 22, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and commercialize a novel therapy for arthrofibrosis using small-molecule inhibitors of interleukin-11. The project aims to develop Novomedix small-molecule anti-inflammatory and antifibrotic drug candidates (NMX) for local application to reduce and potentially reverse...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded MDS II LLC $299,996 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and commercialize the Rotational Femoral Nail System (RFNS), an orthopedic device designed to prevent and correct rotational malalignment in femoral fractures. The RFNS integrates an adjustable rotational mechanism and goniometer to enable precise intraoperative alignment and postoperative adjustments, addressing malrotation complications affecting up to 35% of femoral fracture surgeries. The device is engineered for use in both high-resource and resource-limited healthcare settings. This Phase I effort focuses on finalizing the RFNS design, producing production-equivalent prototypes, and conducting mechanical and clinical verification and validation testing to establish device feasibility and regulatory readiness for 510(k) FDA clearance submission. Preliminary work at the University of Colorado has validated the technology's potential. Performance will occur in Boulder, Colorado, with work concluding August 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $300.0k | 8/28/26 |